Edmonds Duncan Registered Investment Advisors LLC Maintains Stake in Amgen Inc. (NASDAQ:AMGN)

Edmonds Duncan Registered Investment Advisors LLC maintained its position in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the SEC. The firm owned 3,120 shares of the medical research company’s stock at the end of the first quarter. Edmonds Duncan Registered Investment Advisors LLC’s holdings in Amgen were worth $514,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in AMGN. Camelot Portfolios LLC acquired a new position in Amgen during the first quarter valued at approximately $1,429,000. Private Asset Management Inc. boosted its position in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock valued at $589,000 after buying an additional 1,942 shares during the period. Cadence Bank NA boosted its position in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock valued at $554,000 after buying an additional 197 shares during the period. Stillwater Capital Advisors LLC acquired a new position in Amgen during the first quarter valued at approximately $202,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Amgen during the fourth quarter valued at approximately $275,209,000. Institutional investors own 78.87% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) opened at 172.15 on Friday. The firm has a market capitalization of $126.60 billion, a price-to-earnings ratio of 16.35 and a beta of 1.36. The stock’s 50 day moving average price is $172.14 and its 200-day moving average price is $166.19. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 30.17% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter in the previous year, the company posted $2.84 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post $12.56 earnings per share for the current fiscal year.

Several equities analysts have recently commented on AMGN shares. Deutsche Bank AG started coverage on Amgen in a research note on Friday, June 23rd. They set a “hold” rating and a $172.00 target price for the company. Credit Suisse Group reiterated a “hold” rating and set a $178.00 target price on shares of Amgen in a research note on Tuesday, April 4th. ValuEngine cut Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 target price on Amgen and gave the company a “buy” rating in a research note on Monday, June 5th. Finally, Mizuho reiterated a “buy” rating and set a $195.00 target price on shares of Amgen in a research note on Monday, April 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $186.81.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).